Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.
All articles by Judah Gutwein
Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
Mario Sznol, MD, of the Yale University School of Medicine in New Haven, Connecticut, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.
Immunotherapy of Advanced Colorectal Cancer By Enlisting Bystander T Cells
Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.
The Resurgence of Interest in Immune Therapy for Metastatic Renal Carcinoma
Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.
The Promise of PD-1/PD-L1 Antagonists in Treating Metastatic Melanoma
Mario Sznol, MD, comments on the results of his phase 1 study reporting on data from patients with metastatic melanoma treated with nivolumab.
- Loading...
Loading...
Next post in From The Advisory Board
Loading... 
Loading...